

Background

A leading pharmaceutical company aimed to extend the proven success of their RX initiatives to their various OTC lines of business. Recognizing that OTC brands cater to a broader target audience, the company turned to Samsung to develop a new strategy to not only reach this more general market, but also achieve incremental reach against their traditional linear efforts.

RX

Strategy

Leverage Samsung's scale paired with healthcare data segments and measurement solutions to reach hyper-targeted, diagnosed audiences

Results

Audience Quality

CTV + diagnosed audiences proved to be highly efficient in achieving diagnosed audience quality and reaching diagnosed unique viewers.

5.5%

AQ score, above IQVIA's 4.8 benchmark* for this particular diagnosed audience

7.3K

incremental new patient office visits

Efficiency

Samsung remained the most efficient partner on the plan following the 2022 CTV campaign launch

Source: Samsung Ads proprietary ACR data; IQVIA 2022 Campaign Report.

OTC

Strategy

Leverage CTV to reach a less-targeted audience at a lower cost, while achieving incremental reach against existing linear buys

Results

Outcomes

Across multiple OTC brands, Samsung Ads drove significant incremental reach against linear campaigns:

- Dental care brand 1:
 32% incremental lift;
 63% within A25-54
 demo target vs.
 linear's 41%
- Dental care brand 2:
 43% incremental lift;
 72% within A25-54 demotarget vs. linear's 41%
- Vaccine brand:
 15% incremental lift;
 70% within A50+
 demo target vs.
 linear's 78%
- Injectable antiretroviralbrand: 11% incremental lift;
 53% within A25-54 demotarget vs. linear's 52%

Efficiency

The majority of impressions fell within the brand's target audience without the need to pay for additional demo targeting